2020
Association of SLC1A1 Gene Polymorphism With Obsessive Compulsive Disorder in a Sample From Southern India
Shukla T, Nadella R, J. R, Ganesh S, Nestadt G, Purushottam M, Jain S, Reddy Y, Viswanath B. Association of SLC1A1 Gene Polymorphism With Obsessive Compulsive Disorder in a Sample From Southern India. Experimental And Clinical Psychopharmacology 2020, 28: 617-621. PMID: 31985241, DOI: 10.1037/pha0000348.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderTreatment responseAge of onsetSRI treatment responseSignificant associationClinical parametersMini International Neuropsychiatric InterviewGenotype/allele frequenciesSymptom dimensionsSpecialty OCD clinicAdequate trialFull respondersNeuropsychiatric InterviewHealthy controlsBrain volumeGene polymorphismsOCD clinicDisease severityCase-control association analysisSymptom severityOCD patientsOCD casesGenotype frequenciesCompulsive disorderAssociationAdverse childhood experiences in families with multiple members diagnosed to have psychiatric illnesses
Someshwar A, Holla B, Pansari Agarwal P, Thomas A, Jose A, Joseph B, Raju B, Karle H, Muthukumaran M, Kodancha P, Kumar P, Reddy P, Kumar Nadella R, Naik S, Mitra S, Mallappagiri S, Sreeraj V, Balachander S, Ganesh S, Murthy P, Benegal V, Reddy J, Jain S, Mahadevan J, Viswanath B, Rao N, Narayanaswamy J, Sivakumar P, Kandasamy A, Kesavan M, Mehta U, Venkatasubramanian G, John J, Mukherjee O, Purushottam M, Kannan R, Mehta B, Kandavel T, Binukumar B, Saini J, Jayarajan D, Shyamsundar A, Moirangthem S, Vijay Kumar K, Thirthalli J, Chandra P, Gangadhar B, Panicker M, Bhalla U, Chattarji S, Varghese M, Raghu P, Rao M. Adverse childhood experiences in families with multiple members diagnosed to have psychiatric illnesses. Australian & New Zealand Journal Of Psychiatry 2020, 54: 1086-1094. PMID: 32538179, DOI: 10.1177/0004867420931157.Peer-Reviewed Original ResearchConceptsFirst-degree relativesAdverse childhood experience exposureMajor psychiatric conditionsAdverse childhood experiencesObsessive-compulsive disorderSeverity scorePsychiatric conditionsSubstance dependencePsychiatric illnessBipolar disorderAdverse Childhood Experiences International QuestionnaireRisk first-degree relativesChildhood experiencesCo-occurring diagnosesAge of onsetEarly ageInteraction of diagnosisOngoing longitudinal studyPsychiatric diagnosis
2018
Six months' course and outcome of metabolic abnormalities in a cohort of patients with schizophrenia in rural India
Bijjal S, Ganesh S, Rawat V, Agarwal V, Reddy K, Devi N, Kumar C, Christopher R, Thirthalli J. Six months' course and outcome of metabolic abnormalities in a cohort of patients with schizophrenia in rural India. Schizophrenia Research 2018, 201: 415-416. PMID: 29880456, DOI: 10.1016/j.schres.2018.05.016.Peer-Reviewed Original Research
2017
BDNF gene and obsessive compulsive disorder risk, symptom dimensions and treatment response
J R, Ganesh S, Shukla T, Deolankar S, Nadella R, Sen S, Purushottam M, Reddy Y, Jain S, Viswanath B. BDNF gene and obsessive compulsive disorder risk, symptom dimensions and treatment response. Asian Journal Of Psychiatry 2017, 38: 65-69. PMID: 29079096, DOI: 10.1016/j.ajp.2017.10.014.Peer-Reviewed Original ResearchPrevalence and predictors of metabolic syndrome in patients with schizophrenia and healthy controls: A study in rural South Indian population
Rawat V, Ganesh S, Bijjal S, Reddy K, Agarwal V, Devi R, Kumar C, Christopher R, Thirthalli J. Prevalence and predictors of metabolic syndrome in patients with schizophrenia and healthy controls: A study in rural South Indian population. Schizophrenia Research 2017, 192: 102-107. PMID: 28454923, DOI: 10.1016/j.schres.2017.04.039.Peer-Reviewed Original ResearchConceptsPredictors of MetSGeneral population controlsAntipsychotic exposureMetabolic syndromeOdds ratioFemale genderRural south Indian populationInternational Diabetes Federation criteriaDiagnosis of MetSSubgrouping of patientsPhysical activity patternsSouth Indian populationPopulation controlsFederation criteriaClinical parametersSouth IndiaTreatment detailsHealthy controlsIndependent riskLow prevalenceGeneral populationTreatment groupsPatientsSchizophrenia patientsControl group